CClinicalTrials.gg
Status unknownNCT03258333Updated Aug 23, 2017

Small Aortic Annulus - a New Solution to the Old Problem

An observational study in Aortic Valve Replacement, sponsored by The Federal Centre of Cardiovascular Surgery, Russia. Status unknown at 1 site in Russian Federation. Open to participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2017-08-23.

Sponsored by The Federal Centre of Cardiovascular Surgery, Russia · Observational

The sponsor has not verified this record recently (last verified Aug 2017), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
60 Years to 90 Years
Sex
All
01

Study summary

In this prospective single-center study included 60 patients with a severe degenerative aortic stenosis and small aortic annulus (\<21 mm) who underwent standard AVR with stented bioprosthesis (group 1, n=30) and aortic valve reconstruction using autologus pericardium (Ozaki procedure) (group 2, n=30)

Read the detailed description

Aortic valve replacement (AVR) in patients with a small aortic annulus is a challenging problem. Implantation of a small aortic valve sometimes leads to high residual gradients, despite a normally functioning prosthesis. Patients with a small aortic annulus, especially those with a large body surface area, are at higher risk of prosthesis-patient mismatch, which is associated with worse clinical outcomes and decreased survival. The purpose of this study was to compare the hemodynamic performance among the 2 management strategies (standard AVR with stented bioprosthesis and Ozaki procedure) in the context of a small aortic annulus (\<21 mm)

02

Conditions studied

  • Aortic Valve Replacement

Keywords

  • aortic stenosis, aortic valve replacement, pericardium
03

Who can participate

Ages eligible
60 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with severe degenerative aortic stenosis and small aortic annulus (\<21 mm) were enrolled in this study

Inclusion criteria

  • severe degenerative aortic valve stenosis

Exclusion criteria

Exclusion Criteria:

  • redo operation, infective endocarditis
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (actual)
Patient registry
No

Groups and cohorts

  • Stented bioprosthesis

    Standard aortic valve replacement with stented bioprosthesis. Surgery is performed through median sternotomy, aortic and right or bicaval venous cannulation, normothermic perfusion, antegrade cardioplegia with use cardioplegic solution Custodiol. A transverse aortotomy was performed 1 to 2 cm above the right coronary artery. The aortic annulus was thoroughly débrided of calcium. Valve sizing was performed with standard manufacturers' sizers, with selection of the size that would comfortably fit within the aortic annulus. A noneverting suture technique was used in all patients with interrupted horizontal mattress 2-0 braided sutures placed around the aortic annulus, with the pledgets on the ventricular aspect.

    Procedure: aortic valve replacement

  • Ozaki procedure

    Aortic valve reconstruction using autologus pericardium (Ozaki procedure). The autologous pericardium is harvested after routine median sternotomy. Harvested pericardium is then treated with a 0.6% glutaraldehyde solution for 10 min and then rinsed 3 times with sterilized saline each time for 6 min. After resection of the diseased aortic valve cusps, the distance between each commissure is measured using a self-developed sizing instrument. Glutaraldehyde-treated autologous pericardium is trimmed with a self-developed template corresponding to the measured value. The annular margin of the pericardial leaflet is then running-sutured to each annulus with 3-0 monofilament sutures. Commissural coaptation is secured with additional 4-0 monofilament sutures. The coaptation of the 3 cusps is then checked with negative pressure on the left ventricular vent.

    Procedure: aortic valve replacement

Interventions

  • Procedureaortic valve replacement

    Standart AVR using stented stented bioprosthesis aortic valve reconstruction using autologus pericardium

05

What researchers measure

Primary outcomes

  1. Indexed effective orifice area, cm²/m²

    Assessment of aortic valve dimension

    Time frame: 12 months after surgery

Secondary outcomes

  1. prosthesis-patient mismatch (PPM)

    Indicator of the effectiveness of aortic valve replacement

    Time frame: 12 months after surgery

  2. Peak pressure gradient, mm.Hg

    Indicator of the effectiveness of aortic valve replacement

    Time frame: 12 months after surgery

  3. Mean pressure gradient, mm.Hg

    Indicator of the effectiveness of aortic valve replacement

    Time frame: 12 months after surgery

  4. Effective orifice area, EOA, cm²

    Assessment of aortic valve dimension

    Time frame: 12 months after surgery

Other outcomes

  1. Age (years)

    Description and comparison of groups patients

    Time frame: 12 months after surgery

  2. Body mass index, kg/m²

    Description and comparison of groups patients

    Time frame: 12 months after surgery

  3. Body surface area, m²

    Description and comparison of groups patients

    Time frame: 12 months after surgery

  4. Aortic annulus diameter, mm

    Description and comparison of groups patients

    Time frame: 12 months after surgery

  5. Indexed aortic annulus diameter, mm/m²

    Description and comparison of groups patients

    Time frame: 12 months after surgery

  6. Myocardial mass index, g/m²

    Assessment of reverse remodeling of the left ventricle

    Time frame: 12 months after surgery

06

Study locations

1 site
  • FederalCCS
    Penza, 440071, Russian Federation
07

References and documents

Publications

  • Gerosa G, Tarzia V, Rizzoli G, Bottio T. Small aortic annulus: the hydrodynamic performances of 5 commercially available tissue valves. J Thorac Cardiovasc Surg. 2006 May;131(5):1058-64. doi: 10.1016/j.jtcvs.2005.12.034. PubMed 16678590 ↗
  • Ozaki S, Kawase I, Yamashita H, Uchida S, Takatoh M, Hagiwara S, Kiyohara N. Aortic Valve Reconstruction Using Autologous Pericardium for Aortic Stenosis. Circ J. 2015;79(7):1504-10. doi: 10.1253/circj.CJ-14-1092. Epub 2015 Mar 30. PubMed 25818901 ↗
  • Ozaki S, Kawase I, Yamashita H, Uchida S, Nozawa Y, Matsuyama T, Takatoh M, Hagiwara S. Aortic valve reconstruction using self-developed aortic valve plasty system in aortic valve disease. Interact Cardiovasc Thorac Surg. 2011 Apr;12(4):550-3. doi: 10.1510/icvts.2010.253682. Epub 2011 Jan 27. PubMed 21273254 ↗
  • Borger MA, Nette AF, Maganti M, Feindel CM. Carpentier-Edwards Perimount Magna valve versus Medtronic Hancock II: a matched hemodynamic comparison. Ann Thorac Surg. 2007 Jun;83(6):2054-8. doi: 10.1016/j.athoracsur.2007.02.062. PubMed 17532395 ↗
  • Ghoneim A, Bouhout I, Demers P, Mazine A, Francispillai M, El-Hamamsy I, Carrier M, Lamarche Y, Bouchard D. Management of small aortic annulus in the era of sutureless valves: A comparative study among different biological options. J Thorac Cardiovasc Surg. 2016 Oct;152(4):1019-28. doi: 10.1016/j.jtcvs.2016.06.058. Epub 2016 Jul 28. PubMed 27641297 ↗
  • Morita S. Aortic valve replacement and prosthesis-patient mismatch in the era of trans-catheter aortic valve implantation. Gen Thorac Cardiovasc Surg. 2016 Aug;64(8):435-40. doi: 10.1007/s11748-016-0657-9. Epub 2016 May 27. PubMed 27234223 ↗
  • Minardi G, Pergolini A, Zampi G, Pulignano G, Pero G, Sbaraglia F, Pino PG, Cioffi G, Musumeci F. St. Jude Trifecta versus Carpentier-Edwards Perimount Magna valves for the treatment of aortic stenosis: comparison of early Doppler-echocardiography and hemodynamic performance. Monaldi Arch Chest Dis. 2013 Sep;80(3):126-32. doi: 10.4081/monaldi.2013.74. PubMed 24818319 ↗

Individual participant data

Plan to share: Yes

08

Registry details

Key details

Study ID
NCT03258333
Lead sponsor
The Federal Centre of Cardiovascular Surgery, Russia
Responsible party
Mikulyak Artur (Principal Investigator, Cardiovascular surgeon, The Federal Centre of Cardiovascular Surgery, Russia) — Principal investigator
First posted
Aug 23, 2017
Start date
Feb 18, 2017
Primary completion
Jan 1, 2022 (estimated)
Completion
Jul 1, 2022 (estimated)
Last update
Aug 23, 2017

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion